Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R21GM144851-02 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Vanderbilt University | OTHER |
| National Institute of General Medical Sciences (NIGMS) | NIH |
Not provided
Not provided
Not provided
Not provided
In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator specimen collected biospecimens.
Analyses will include traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, transcriptomics, and pathogen genomic sequencing in both sets of samples. This data will allow the assessment of the feasibility, integrity, and scientific value of remnant samples compared to research coordinator samples collected at the bedside for mechanistic sepsis research.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with Sepsis | Adult patients (18 years or older) meeting Sepsis-3 criteria within 6 hours of emergency department admission. Patients will be excluded with the following conditions: traumatic injury, cardiac arrest, stroke, comfort measures only. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Difference in traditional biomarkers, proteomics, pathogen sequencing, and metabolomics/lipidomics between prospectively collected biospecimens and remnant biospecimens. | 01/2024 |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of traditional biomarkers in all samples | Traditional biomarkers to be measured in remnant and research specimens including inflammatory and endothelial-related biomarkers. | 1/2024 |
| Measurement of proteomics in all samples |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients with Sepsis-3 presenting to eligible emergency departments.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christopher Seymour, M.D. | University of Pittsburgh / UPMC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Remnant/leftover blood samples collected after usual patient care in comparison to newly obtained blood samples to evaluate 1) validity and stability of remnant blood samples vs fresh, newly obtained blood samples. 2) blood proteins, biomarkers, and other -omics
Proteomics to be measured in remnant and research specimens to capture over 50 different plasma proteins.
| 1/2024 |
| Measurement of metabolomics/lipidomics in all samples | Metabolomics and lipidomics to be measured in remnant and research specimens to capture organic acids, amino acids, and phospholipids. | 1/2024 |
| Pathogen sequencing in all samples | Pathogen sequencing will be performed on all remnant and research specimens to precisely identify the causative strain(s) in the infection. | 1/2024 |
| D013568 |
| Pathological Conditions, Signs and Symptoms |